Wall Street analysts rolled out fresh coverage on five companies Tuesday, delivering a mix of bullish calls and one neutral stance that caught investors' attention across several sectors.

Leading the optimism, Raymond James analyst Rick Patel initiated coverage on Levi Strauss & Co. (LEVI) with an Outperform rating and set a price target of $26. The denim giant closed at $21.23 on Monday, meaning Patel sees solid upside potential in the iconic apparel maker.

The most aggressive price target of the day went to Spruce Biosciences, Inc. (SPRB), where Oppenheimer analyst Leland Gershell initiated coverage with an Outperform rating and a $283 price target. That represents substantial upside from the stock's $82.82 Monday close, signaling strong conviction in the biotech company's prospects.

Cellectis SA (CLLS) also earned a bullish nod, with Clear Street analyst Bill Maughan starting coverage with a Buy rating and $9 price target. The biotech stock finished Monday's session at $4.69, giving it plenty of room to run if Maughan's thesis plays out.

Meanwhile, Jones Trading analyst Catherine Novack initiated coverage on Septerna, Inc. (SEPN) with a Buy rating and $43 price target. Septerna shares closed at $29.47 on Monday, positioning the stock for potential gains according to Novack's analysis.

The lone neutral call came from Loop Capital, which initiated coverage on Brunswick Corporation (BC) with a Hold rating and $74 price target. Interestingly, Brunswick shares closed at $76.64 on Monday, meaning the stock is already trading above the analyst's target price, suggesting limited upside in Loop Capital's view.

These coverage initiations span a diverse range of industries, from the heritage brand appeal of Levi Strauss to cutting-edge biotechnology plays and recreational manufacturing. The variety reflects Wall Street's ongoing effort to identify value and growth opportunities across different market segments as analysts expand their coverage universes.